In June of this year, the Federal Circuit panel in Ariosa Diagnostics, Inc. v. Sequenom, Inc. invalidated a patent on the grounds of patent-ineligible subject matter. 788 F.3d 1371 (Fed. Cir. 2015). While the case is one of...more
11/5/2015
/ Declaratory Rulings ,
DNA ,
En Banc Review ,
Life Sciences ,
Mootness ,
Myriad-Mayo ,
Patent Infringement ,
Patent Invalidity ,
Patent-Eligible Subject Matter ,
Patents ,
Petition For Rehearing ,
Preemption ,
Product of Nature Doctrine ,
Section 101